Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide-Reference-Cited by-同舟云学术

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

Published:2013-07 Issue:7 Volume:24 Page:1802-1807
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Noonan K.L.,North S.,Bitting R.L.,Armstrong A.J.,Ellard S.L.,Chi K.N.

Funder

Janssen, Medivation, Sanofi aventis, Dendreon, Active Biotech/Ipsen, Imclone/Ely Lilly, BMS.

Chi: Honoraria from Janssen and Astellas; research funding from Janssen

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/7/1802/472022/mdt138.pdf

Reference17 articles.

1. Canadian Cancer SocietyProstate Cancer Statistics. Available from URL: http://www.cancer.ca/canada-wide/about%20cancer/cancer%20statistics/stats%20at%20a%20glance/prostate%20cancer.aspx (19 July 2012, date last assessed)

2. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Philip;N Engl J Med,2010

3. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

4. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial;de Bono;The Lancet,2010

5. Increase survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

Cited by 287 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2023-10

2. Bipolar Androgen Therapy: When Excess Fuel Extinguishes the Fire;Biomedicines;2023-07-24

3. Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer;Expert Review of Anticancer Therapy;2022-11-02

4. The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations;Expert Review of Clinical Pharmacology;2022-11-02

5. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study;The Lancet Oncology;2022-11